Authors
Latest:
How to Rally a Team Around Building a New BusinessThree key components to scaling quickly—while maintaining purpose.
Latest:
Optimizing Pharma Content for Faster Product SubmissionsPharma and life science companies can reduce time to market by optimizing regulatory content management and submission processes.
Latest:
Pharma’s Remote Work Cybersecurity ChallengeThe massive shift to remote work has seen pharma companies increasingly targeted by malicious actors seeking out weaker points across the business ecosystem. But with the right mix of technology and mindset, organizations can prepare against threats in the future.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Biotech Companies Deal with Silicon Valley Bank CollapseSilicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
Latest:
A Rare-Disease Must? Building Long-Term RelationshipsThe importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Latest:
All in on AI is Not the Solution in Life Sciences and Health CareAlthough life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.
Latest:
In life sciences, the metaverse opportunity knocksHere are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Latest:
Three Ways Life Sciences Can Educate Stakeholders About BiosimilarsThere are several strategies life sciences companies can use to benefit from biosimilars.
Latest:
Moving Beyond Traditional Approaches to Alzheimer’s DiseaseThe recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
Latest:
Beyond the Data: Is Blockchain the Answer to Improving Global Health?The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Latest:
The Silver Lining Of Innovation in Genetic MedicineFailed efforts do not overshadow field’s progress, resolve.
Latest:
Seven Essential Attributes for Investing in Life SciencesThese factors provide investors with enough information to identify promising investment opportunities.
Latest:
Value-Based Planning Uncovers True Drivers of Cost Across Life Sciences OrganizationsExplicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.
Latest:
Developing a Product Launch Strategy for an Orphan DrugCommercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Latest:
Optimizing the Value of Real-World Evidence ProjectsMark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.
Latest:
Navigating PV Divergence: Compliance Tips for New EntrantsWith small biotechs facing similar expectations as large pharma in drug safety and pharmacovigilance, despite less resources, identifying the key differences between US and EU requirements can help these companies craft a practical path to multi-region compliance.
Latest:
COVID and AMR: Crisis Reframes Antibiotics FightThe redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
How MSLs Can Enrich Scientific Exchange with Customer InsightIn today‘s environment, medical science liaisons (MSLs) must call on digital solutions to make use of the right data and encourage the right conversations to take place.
Latest:
What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug DevelopmentIndustry has shown it can overcome challenges en route to creating new therapies.
Latest:
Improving Readiness for Volume-Based Procurement in ChinaVolume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
